Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia

Recruiting N/A Interventional Study
Ventricular Tachycardia Ischemic Heart Disease Sustained VT
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
40 (estimated)
Sponsor
Pasquale Santangeli · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
ASCEND is a randomized controlled open-label pilot study evaluating the safety and effectiveness of pulsed field ablation (PFA) with the novel FARAPOINT catheter compared to the standard radiofrequency (RFA) ablation with ThermoCool ST/FlexAbility SE/ThermoCool ST SF/TactiFlex SE of ventricular tachycardia (VT) in the patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: must meet all of the following: 1. Age ≥18 years. 2. Ischemic heart disease with prior myocardial infarction. 3. Left ventricular ejection fraction ≥20% estimated by transthoracic echocardiography (TTE) within 90 days prior to enrollment. 4. Documented sustained monomorphic VT w…
Contacts

Pasquale Santangeli, MD, PhD

216-445-1940

santanp3@ccf.org

CONTACT

Yuki Kuramochi, BSN, RN

216-445-4063

kuramoy@ccf.org

CONTACT